Treatment of Familial Mediterranean Fever with Anakinra
2007; American College of Physicians; Volume: 146; Issue: 11 Linguagem: Inglês
10.7326/0003-4819-146-11-200706050-00023
ISSN1539-3704
AutoresRakiba Belkhir, L. Moulonguet-Doleris, É. Hachulla, J Prinseau, A Baglin, Thomas Hanslik,
Tópico(s)Kawasaki Disease and Coronary Complications
ResumoLetters5 June 2007Treatment of Familial Mediterranean Fever with AnakinraRakiba Belkhir, MD, Luc Moulonguet-Doleris, MD, Eric Hachulla, MD, PhD, Jacques Prinseau, MD, Alain Baglin, MD, and Thomas Hanslik, MD, PhDRakiba Belkhir, MDFrom Hôpital Ambroise Paré, Boulogne 92104, France.Search for more papers by this author, Luc Moulonguet-Doleris, MDFrom Hôpital Ambroise Paré, Boulogne 92104, France.Search for more papers by this author, Eric Hachulla, MD, PhDFrom Hôpital Ambroise Paré, Boulogne 92104, France.Search for more papers by this author, Jacques Prinseau, MDFrom Hôpital Ambroise Paré, Boulogne 92104, France.Search for more papers by this author, Alain Baglin, MDFrom Hôpital Ambroise Paré, Boulogne 92104, France.Search for more papers by this author, and Thomas Hanslik, MD, PhDFrom Hôpital Ambroise Paré, Boulogne 92104, France.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-146-11-200706050-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: About 5% to 10% of patients with familial Mediterranean fever (FMF) have no clinical response to colchicine therapy, and no treatment recommendations exist for these cases (1). Interleukin-1 (IL-1) is a major proinflammatory cytokine that is increased in activity by pyrin, which is elevated in FMF (2, 3). Thus, blockade of IL-1 could in theory control the disease.Objective: To describe a woman with FMF who was refractory to colchicine treatment but who responded clinically to anakinra therapy, an IL-1–receptor antagonist.Case Report: A 68-year-old woman with FMF was treated with colchicine since her teens. The diagnosis was based ...References1. Onen F. Familial Mediterranean fever. Rheumatol Int. 2006;26:489-96. [PMID: 16283319] CrossrefMedlineGoogle Scholar2. Gumucio DL, Diaz A, Schaner P, Richards N, Babcock C, Schaller M, et al. Fire and ICE: the role of pyrin domain-containing proteins in inflammation and apoptosis. Clin Exp Rheumatol. 2002;20:S45-53. [PMID: 12371636] MedlineGoogle Scholar3. Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A. 2006;103:9982-7. [PMID: 16785446] CrossrefMedlineGoogle Scholar4. Peeters AC, Netea MG, Janssen MC, Kullberg BJ, Van der Meer JW, Thien T. Pro-inflammatory cytokines in patients with essential hypertension. Eur J Clin Invest. 2001;31:31-6. [PMID: 11168436] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Hôpital Ambroise Paré, Boulogne 92104, France.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byStructure, Activation and Regulation of NLRP3 and AIM2 InflammasomesThe Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative ReviewLong-term effectiveness and safety of canakinumab in pediatric familial Mediterranean fever patientsIL-1 mediated autoinflammatory diseasesUpdate on the management of colchicine resistant Familial Mediterranean Fever (FMF)Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysisFamilial Mediterranean FeverInterventions for reducing inflammation in familial Mediterranean feverNationwide Experience With Off-Label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever PatientsColchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatmentsCanakinumab for the treatment of familial Mediterranean feverFamilial Mediterranean Fever: Recent Developments in Pathogenesis and New Recommendations for ManagementAnti-interleukin-1 treatment in 26 patients with refractory familial mediterranean feverIL-1β and Caspase-1 Drive Autoinflammatory Disease Independently of IL-1α or Caspase-8 in a Mouse Model of Familial Mediterranean FeverWhen to Suspect Autoinflammatory/Recurrent Fever SyndromesAutoinflammatory diseases and kidney involvementCanakinumab investigated for treating familial Mediterranean feverBiologic therapy in familial Mediterranean feverOld Dogs, New Tricks: Monogenic Autoinflammatory Disease UnleashedApproach to the patients with inadequate response to colchicine in familial Mediterranean feverAnti-IL-1 treatment in familial Mediterranean fever and related amyloidosisAnakinra induce la remisión completa del síndrome nefrótico en un paciente con fiebre mediterránea familiar y amiloidosisAnakinra induces complete remission of nephrotic syndrome in a patient with familial Mediterranean fever and amyloidosisInterventions for reducing inflammation in familial Mediterranean feverPathogenesisMonogenic autoinflammatory diseasesInterleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and PerspectivesAutoinflammatory SyndromesClassic Autoinflammatory DiseasesEvidence-based recommendations for the practical management of Familial Mediterranean FeverFamilial mediterranean fever: a fascinating model of inherited autoinflammatory disorderIL-1β Biological Treatment of Familial Mediterranean FeverEfficacy and Safety of Biologic Treatments in Familial Mediterranean FeverAutoinflammation: From monogenic syndromes to common skin diseasesNovel Therapeutics for the Treatment of Familial Mediterranean Fever: From Colchicine to BiologicsBiological Treatments: New Weapons in the Management of Monogenic Autoinflammatory DisordersBiologic drugs in autoinflammatory syndromesRilonacept for Colchicine-Resistant or -Intolerant Familial Mediterranean Fever A Randomized TrialPhilip J. Hashkes, MD, MSc, Steven J. Spalding, MD, Edward H. Giannini, DrPH, MSc, Bin Huang, PhD, Anne Johnson, CCRP, Grace Park, MD, MPH, Karyl S. Barron, MD, Michael H. Weisman, MD, Noune Pashinian, MD, Andreas O. Reiff, MD, Jonathan Samuels, MD, Dowain A. Wright, MD, PhD, Daniel L. Kastner, MD, PhD, and Daniel J. Lovell, MD, MPHDramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failureFocus sur les inhibiteurs de l’interleukine 1Near and Middle EastHereditary periodic fever syndromesInterleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the LiteratureThe NLRP3 inflammasome in health and disease: the good, the bad and the uglyFamilial Mediterranean fever—A reviewThe Inflammasomes in Kidney DiseaseGain-of-Function Pyrin Mutations Induce NLRP3 Protein-Independent Interleukin-1β Activation and Severe Autoinflammation in MiceCurrent data on familial Mediterranean feverActualités sur la fièvre méditerranéenne familialeThe inflammasome regulatory pathway and infections: Role in pathophysiology and clinical implicationsHereditary recurrent feversSkin Signs of Other Systemic DiseasesHereditary Periodic Fever SyndromesLes biothérapies hors AMM dans les maladies systémiquesTreatment of autoinflammatory syndromesIL-1-AntagonistenTransmission of Familial Mediterranean Fever Mutation After Bone Marrow Transplantation and Successful Treatment With AnakinraInflammasome and IL-1β-Mediated DisordersAutoinflammatory conditions: when to suspect? How to treat?Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: Finding the right balance in response to danger signalsBlockade of interleukin 1 in type 1 diabetes mellitusUrticarial Syndromes and AutoinflammationTherapy of autoinflammatory syndromesEmpfehlungen zur Therapie mit Interleukin-1β-blockierenden WirkstoffenAdvances in the understanding of familial Mediterranean fever and possibilities for targeted therapyCurrent perspectives on familial Mediterranean feverPeriodic Fever SyndromesHorror Autoinflammaticus : The Molecular Pathophysiology of Autoinflammatory DiseaseAnakinra en la fiebre mediterránea familiarDysregulation of innate immunity: hereditary periodic fever syndromesSuccessful treatment of idiopathic recurrent pericarditis in children with interleukin-1β receptor antagonist (anakinra): An unrecognized autoinflammatory disease?The Effects of Interleukin-1 β in Tumor Necrosis Factor- α -Induced Acute Pulmonary Inflammation in MiceQuoi de neuf dans les maladies auto-inflammatoires ?Syndromes auto-inflammatoires et grossesseTreatment strategies for amyloid A amyloidosisAnakinra: New therapeutic approach in children with Familial Mediterranean Fever resistant to colchicineAnakinra chez un enfant souffrant de fièvre méditerranéenne familiale résistante à la colchicineDiagnosis and Management of Autoinflammatory Diseases in ChildhoodAutoinflammatory diseases: an update of clinical and genetic aspectsThe future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritisAuto inflammatory syndromes: Diagnosis and treatmentIL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in miceRhumatismes auto-inflammatoires: stratégie diagnostique et traitementAnakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky 5 June 2007Volume 146, Issue 11Page: 825-826KeywordsAbdominal painBiomarkersC-reactive proteinsColchicineCytokinesFeversInflammationPrimary hypertensionRenal failureSalivary glands ePublished: 5 June 2007 Issue Published: 5 June 2007 Copyright & PermissionsCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Referência(s)